Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay.

Baert A1, Depuydt J1, Van Maerken T2, Poppe B3, Malfait F3, Van Damme T3, De Nobele S3, Perletti G1, De Leeneer K3, Claes KB3, Vral A1.

Author information

Abstract

Breast cancer risk drastically increases in individuals with a heterozygous germline BRCA1 or BRCA2 mutation, while it is estimated to equal the population risk for relatives without the familial mutation (non-carriers). The aim of the present study was to use a G2 phase-specific micronucleus assay to investigate whether lymphocytes of healthy BRCA2 mutation carriers are characterized by increased radiosensitivity compared to controls without a family history of breast/ovarian cancer and how this relates to healthy non-carrier relatives. BRCA2 is active in homologous recombination, a DNA damage repair pathway, specifically active in the late S/G2 phase of the cell cycle. We found a significantly increased radiosensitivity in a cohort of healthy BRCA2 mutation carriers compared to individuals without a familial history of breast cancer (P=0.046; Mann-Whitney U test). At the individual level, 50% of healthy BRCA2 mutation carriers showed a radiosensitive phenotype (radiosensitivity score of 1 or 2), whereas 83% of the controls showed no radiosensitivity (P=0.038; one-tailed Fisher's exact test). An odds ratio of 5 (95% CI, 1.07-23.47) indicated an association between the BRCA2 mutation and radiosensitivity in healthy mutation carriers. These results indicate the need for the gentle use of ionizing radiation for either diagnostic or therapeutic use in BRCA2 mutation carriers. We detected no increased radiosensitivity in the non-carrier relatives.

PMID:: 28184943
DOI:: 10.3892/or.2017.5407

[PubMed - in process]

From HuGE Literature Finder Database

This database contains published literature on genetic associations and other human genome epidemiology

Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay.
Oncology reports 2017 Mar 37 (3): 1379-1386.
Baert Annelot, Depuydt Julie, Van Maerken Tom, Poppe Bruce, Malfait Fransiska, Van Damme Tim, De Nobele Sylvia, Perletti Gianpaolo, De Leeneer Kim, Claes Kathleen B M, Vral An
BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
Gynecologic oncology 2017 Feb .
Eoh Kyung Jin, Park Ji Soo, Park Hyung Seok, Lee Seung-Tae, Han Jeongwoo, Lee Jung-Yun, Kim Sang Wun, Kim Sunghoon, Kim Young Tae, Nam Eun
High-risk epithelial ovarian cancer patients for hereditary ovarian cancer.
The journal of obstetrics and gynaecology research 2017 Feb .
Chirasophon Seksit, Manchana Tarinee, Teerapakpinyo Chinacho
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
British journal of cancer 2017 Feb .
Golan Talia, Sella Tal, O'Reilly Eileen M, Katz Matthew H G, Epelbaum Ron, Kelsen David P, Borgida Ayelet, Maynard Hannah, Kindler Hedy, Friedmen Eitan, Javle Milind, Gallinger Stev
Telomere length is predictive of breast cancer risk in BRCA2 mutation carriers.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2017 Feb .
Thorvaldsdottir Birna, Aradottir Margret, Stefansson Olafur A, Bodvarsdottir Sigridur K, Eyfjörd Jorunn